Deal facts
- Buyer
- KOHLBERG / MONTAGU
- Target
- TELEFLEX OEM BUSINESS
- Deal value
- Not disclosed
- Announced
- 22 March 2026
- Status
- In review
- Sector
- Healthcare
- Country
- Not stated
- Consideration
- Not stated
Sources
KOHLBERG / MONTAGU has agreed to acquire the TELEFLEX OEM Business in a transaction announced on 22 March 2026. The deal involves a company operating within the NaceV2Sector_C_32.50 classification, though the specific monetary value and consideration structure remain undisclosed. No details regarding the target country or the final completion date are currently available in the public record. The transaction is currently subject to regulatory approval and remains in the review phase.
The acquisition represents a significant strategic move for the private equity firm, which has entered the market to secure a stake in this specific business unit. While the exact financial terms have not been revealed, the deal structure indicates a formal agreement between the buyer and the target entity. The parties involved are proceeding with the necessary steps to finalise the transaction, pending the outcome of regulatory assessments. The status of the deal remains active as the review process continues.
Weekly digest
Join Exit Mode Insider
Ten deal briefs a week, founder commentary, and the patterns worth paying attention to.
Join Exit Mode Insider, £12/moDeal timeline
1 update- CMA invitation to comment
KOHLBERG / MONTAGU to acquire TELEFLEX OEM BUSINESS
KOHLBERG / MONTAGU to acquire TELEFLEX OEM BUSINESS
EU DG COMP
Explore
Browse adjacent archives
Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.
Similar deals
Similar deals
Other Healthcare M&A activity tracked by Exit Mode.
SK CAPITAL to acquire SWIXX BIOPHARMA
SK CAPITAL has agreed to acquire SWIXX BIOPHARMA in a transaction announced on 8 March 2026. The deal involves the biopharmaceutical sector, specifically within the whol…
- Buyer
- SK CAPITAL
- Target
- SWIXX BIOPHARMA
- Deal value
- Not disclosed
- Deal type
- unknown
EQT to acquire Oxford Biomedica plc
EQT has agreed to acquire Oxford Biomedica plc, a UK-based CDMO and viral vector specialist, in a transaction announced on 25 February 2026. The specific financial terms…
- Buyer
- EQT
- Target
- Oxford Biomedica plc
- Deal value
- Not disclosed
- Deal type
- unknown
GTCR to acquire ZENTIVA
GTCR has agreed to acquire ZENTIVA in a transaction announced on 19 February 2026. The deal involves the pharmaceutical sector, classified under NaceV2Sector_C_21. No fi…
- Buyer
- GTCR
- Target
- ZENTIVA
- Deal value
- Not disclosed
- Deal type
- unknown
WARBURG PINCUS to acquire SEBIA
WARBURG PINCUS has agreed to acquire SEBIA in a transaction announced on 12 November 2025. The deal involves a company operating across multiple industrial sectors, incl…
- Buyer
- WARBURG PINCUS
- Target
- SEBIA
- Deal value
- Not disclosed
- Deal type
- unknown
CAPVEST to acquire STADA GROUP
CAPVEST has agreed to acquire STADA GROUP in a transaction announced on 11 November 2025. The deal involves a company operating within the pharmaceutical manufacturing s…
- Buyer
- CAPVEST
- Target
- STADA GROUP
- Deal value
- Not disclosed
- Deal type
- unknown
Buyer history
KOHLBERG / MONTAGU
See every published Exit Mode archive entry where this buyer appears.
View buyer profileMethodology
How this page is built
Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.
Back to the archive
